Zobrazeno 1 - 10
of 35
pro vyhledávání: '"F W, Busch"'
Publikováno v:
Aktuelle Dermatologie. 30:474-477
Seit kurzem werden Inhibitoren des Rezeptors fur epidermalen Wachstumsfaktor (EGF) in der Therapie fortgeschrittener, chemotherapieresistenter Karzinomerkrankungen, wie dem kolorektalen Karzinom und dem nicht-kleinzelligen Bronchialkarzinom eingesetz
Autor:
H. J. Schmeck-Lindenau, Heidrun Ziegler, C. Michalski, F. Weiße, Th. Barthel, U. Tholl, R. Mühler, O. Schilling, C. Diaz, D. Baaske, W. Thiel, H. Zaun, Daniel Mischke, C. Seidl, A.-K. Pfeiffer, N. Blödorn-Schlicht, Susanne Suckow, Lutz Kowalzick, W. Werner, Hans-Peter Baum, J.-M. Pönnighaus, Gerhard Wagner, D. Hammerschmidt, V. Schirmer, O. Hölig, C. Lohse, W. Weyers, Gunnar Wagner, Lena Eickenscheidt, Th. Waldmann, A. Barghorn, E. Schaarschmidt, A. Ott, Michael Max Sachse, V. Steinkraus, Michael Komar, D. Ehrich, D. Friedmann, R. A. Herbst, D. Iliev, A. Mamada, B E Schell, A. Frank, C. Wickenhauser, F. W. Busch, Matthias Suckow, Roland Blum, J. Mörtl
Publikováno v:
Dermatologie von Fall zu Fall: Spannende Kasuistiken aus der klinischen Praxis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5f1f714f6567b877adc372584d262bf8
https://doi.org/10.1055/b-002-57171
https://doi.org/10.1055/b-002-57171
Autor:
F. U. Weiss, Bahija Jallal, F. W. Busch, W.-D. Ludwig, Bühring Hj, H.-D. Waller, Axel Ullrich, I. Sures, Rupert Handgretinger
Publikováno v:
Blood. 86:1916-1923
The class I receptor tyrosine kinase (RTK) HER2 is an oncoprotein that is frequently involved in the pathogenesis of tumors of epithelial origin. Here we report mRNA expression in peripheral blood and bone marrow cells from healthy donors in hematopo
Publikováno v:
Annals of Hematology. 64:A132-A136
Perturbations of hematopoietic regulation ranging from transient granulocytopenia to rare cases of bone marrow failure are associated with infections due to hepatitis A virus (HAV). In an attempt to elucidate the pathogenetic mechanisms we had previo
Publikováno v:
Blut. 60:219-222
Drug-induced myelotoxicity is usually the dose-limiting factor of treatment of malignant tumors with cytostatic drugs. Suppression of in vitro myelopoiesis (CFU-GM) by cytostatics may be a suitable model reflecting the in vivo situation. Thus the inh
Autor:
F W Busch, Frank Bohnenstengel, Heyo K. Kroemer, Dagmar Busse, E Schweizer, Michel Eichelbaum, P Fischer, K Schumacher, J Opalinska
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 15(5)
PURPOSE The alkylating anticancer agent cyclophosphamide (CP) is a prodrug that undergoes a complex metabolism in humans producing both active and inactive metabolites. In parallel, unchanged CP is excreted via the kidneys. The aim of this study was
Publikováno v:
Bone marrow transplantation. 19(7)
Granulocyte colony-stimulating factor (G-CSF) is considered to play a pivotal role in hemopoietic regulation, Its pharmacological application is reported to shorten chemotherapy-induced neutropenia as well as time to engraftment in patients after bon
Autor:
H J, Bühring, I, Sures, B, Jallal, F U, Weiss, F W, Busch, W D, Ludwig, R, Handgretinger, H D, Waller, A, Ullrich
Publikováno v:
Blood. 86(5)
The class I receptor tyrosine kinase (RTK) HER2 is an oncoprotein that is frequently involved in the pathogenesis of tumors of epithelial origin. Here we report mRNA expression in peripheral blood and bone marrow cells from healthy donors in hematopo
Autor:
H J, Bühring, R, Herbst, G, Kostka, B, Bossenmaier, I, Bartke, H, Kropshofer, H, Kalbacher, F W, Busch, C A, Müller, J, Schlessinger
Publikováno v:
Cancer research. 53(18)
The function of the steel factor receptor, p145c-kit, in patient-derived acute myeloblastic leukemia (AML) cells was investigated. Steel factor stimulation of AML cells coexpressing p145c-kit and the progenitor cell antigen CD34 resulted in complete
Autor:
G, Ehninger, B, Proksch, T, Wanner, U, Schuler, F W, Busch, H, Schmidt, E, Schleyer, K, Jaschonek, W, Hiddemann
Publikováno v:
Leukemia. 6(6)
Cytosine arabinoside (ara-C) is one of the most active compounds in the treatment of acute leukemias. In the majority of current protocols ara-C is combined with other cytotoxic agents in an attempt to increase antileukemic activity. The present stud